sults of a therapeutic exploratory Phase II dose- finding study randomizing 84 patients. The study evaluated the efficacy, safety and tolerability of 3 doses of cadazolid (administered orally, twice-daily) versus vancomycin, as an active reference, (125 mg administered orally, four times daily) for 10 days.
Posted: 2012-12-21 07:43:00